Unity Biotechnology Inc (NASDAQ: UBX) shares are trading lower by 19.8% to $1.10 Wednesday morning after the company announced a $25 million common stock offering.
What Else?
Unity says the company intends to use the net proceeds from the proposed offering to fund the ongoing clinical development of UBX1325, including the BEHOLD and ENVISION studies, and other general corporate purposes, including working capital, operating expenses and capital.
See Also: Here's How Much You'd Have Now If You Invested $1,000 In Bitcoin, Ethereum And Dogecoin 5 Years Ago
According to data from Benzinga Pro, Unity Biotechnology has a 52-week high of $3.64 and a 52-week low of $0.55.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read at Benzinga